• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics, Inc. - Common Stock (NQ:CYT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 3.070 (100)
Ask (Size) 3.140 (105)
Prev. Close 3.020
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 35,998,024
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
March 07, 2024
From Cyteir Therapeutics
Via Business Wire
News headline image
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
October 12, 2023
From Cyteir Therapeutics
Via Business Wire

Performance

More News

Read More
News headline image
Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher ↗
June 30, 2023
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
June 30, 2023
Via Benzinga
News headline image
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
June 30, 2023
Via Spotlight Growth
News headline image
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
June 30, 2023
Via Benzinga
News headline image
Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May ↗
June 30, 2023
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
June 30, 2023
Via Benzinga
News headline image
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
June 30, 2023
From Cyteir Therapeutics
Via Business Wire
News headline image
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
June 03, 2023
From Cyteir Therapeutics
Via Business Wire
News headline image
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 10, 2023
From Cyteir Therapeutics, Inc.
Via Business Wire
News headline image
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 23, 2023
From Cyteir Therapeutics
Via Business Wire
News headline image
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
February 06, 2023
From Cyteir Therapeutics
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
February 03, 2023
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗
January 30, 2023
Via Benzinga
News headline image
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
January 19, 2023
From Cyteir Therapeutics
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023 ↗
January 20, 2023
Via Benzinga
News headline image
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From Cyteir Therapeutics
Via Business Wire
News headline image
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
October 12, 2022
From Cyteir Therapeutics
Via Business Wire
News headline image
5 Value Stocks In The Healthcare Sector ↗
September 12, 2022
Via Benzinga
News headline image
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From Cyteir Therapeutics
Via Business Wire
News headline image
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022
From Cyteir Therapeutics
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
September 09, 2022
Via Benzinga
News headline image
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 01, 2022
From Cyteir Therapeutics
Via Business Wire
News headline image
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗
July 27, 2022
Via Benzinga

Frequently Asked Questions

Is Cyteir Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cyteir Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cyteir Therapeutics, Inc. - Common Stock trade on?
Cyteir Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cyteir Therapeutics, Inc. - Common Stock?
The ticker symbol for Cyteir Therapeutics, Inc. - Common Stock is CYT on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap